Brief: Neovacs Announces Results Of Its Phase IIb Clinical Study Of IFnalpha Kinoid In Lupus
09/04/2019 06:32
April 9 (Reuters) - NEOVACS SA ALNEV.PA :
* REG-NEOVACS ANNOUNCES THE FULL RESULTS OF ITS PHASE IIB
CLINICAL
STUDY OF IFNALPHA KINOID IN LUPUS - 13TH INTERNATIONAL LUPUS
CONGRESS 2019
* RESULTS CONFIRMED THAT TREATMENT WITH IFN-ALPHA KINOID
INDUCED A
STRONG IMMUNE RESPONSE: 91.4% OF TREATED PATIENTS PRODUCE
NEUTRALISING POLYCLONAL ANTIBODIES AGAINST INTERFERON ALPHA.
* RESULTS MUST BE ASSESSED FURTHER IN A PHASE III CLINICAL
PROGRAM.
Source text for Eikon: ID:nGNE67Y219
Further company coverage: ALNEV.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Neovacs SA
See all newsBrief: Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology
Brief: Neovacs Presented Latest Results On Its Vaccine Candidates Targeting Allergies
Brief: Neovacs H1 Gross Cash Position Down At EUR 6.2 Mln
Brief: Neovacs: Signature Of Trust Agreement For Equitization Of Bonds Redeemable In Shares With Share Warrants
Brief: Neovacs Launches A Public Offering Of Bonds Redeemable In Shares With Stock Warrants